Committed to the development
of innovative single domain antibody drugs
About NovamabNovamab is a clinical-stage biotech company dedicated to creating life-changing therapies for patients through innovative VHH technology. We take pride in our highly differentiated and innovative product pipeline, which targets high-potential markets such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).
Our most advanced project, an inhaled IL-4R VHH, has progressed to Phase II clinical trials, while our inhaled TSLP VHH is preparing to enter Phase IB proof-of-concept studies. Additionally, we are actively developing several bispecific and oral VHH antibody products aimed at treating inflammatory bowel disease (IBD).
About novamab
Luoqi Biotechnology has been listed as one of the top 10 most promising biopharmaceutical companies in China in 2025
Dr. Wan Yakun has been selected for the "Oriental Talents Program" in Shanghai in 2025
Inhalation based lL-4Rα VHH antibody drug LQ036 is in Phase IIb clinical development in China
About novamab
The first patient to receive inhaled IL4R VHH antibody drug LQ036 after completing Phase IIa clinical study
Novamab has been listed on the 2024 ChinaVenture 100 Future Unicorn ranking
Novamab has been ranked among the top 10 most promising biopharmaceutical companies in the 2024 Huayi Chart
Completed a Series B funding round of nearly 300 million yuan
Dr. Yakun Wan has been selected as a 2024 Pudong New Area "Shanghai Pearl Leading Talent"
About novamab
Chinese clinical trial of inhaled TSLP VHH antibody drug LQ043H was approved by CDE
Ranked on the "Future Unicorn 30" list of Zhiyin Innovation New Drugs
LQ036 Chinese Clinical Phase I Approval for COPD Indications
Recognized as a "National Intellectual PropertyAdvantage Enterprise"
Completed Series B financing of over 100 million yuan
About novamab
LQ036 was approved for phase I clinical use in China
500L Pichia pastoris GMP workshop completed decoration and put into production
Novamab was selected as
Novamb won the nomination award of of
About novamab
LQ036 was approved for phase I clinical use in Australia
Dr. Wan Yakun was selected as "Outstanding Innovation and Entrepreneurship Talents in Zhangjiang National Independent Innovation Demonstration Zone"
Recognized as "Shanghai Patent Pilot Enterprise"
About novamab
Won the title of "the most growing entrepreneurial enterprise in the 2020 China Overseas Chinese Pioneer Park"
"Top 50 Most Innovative Biopharmaceutical Enterprises in China"
Recognized as "Shanghai High-tech Enterprise"
About novamab
Selected for the "2019 Insight Zhangjiang Corporate List - Life Science Sector - New Force Enterprises"
Passed the certification of "GB/T 29490-2013 Intellectual Property Management System"
About novamab
Selected into the "Top 6 Start-up Group of the 7th China Innovation and Entrepreneurship Competition Biomedical Industry Finals"
Awarded as "Outstanding Enterprise (Start-up Group) in the 7th China Innovation and Entrepreneurship Competition"
Awarded the "Winner of the 7th China Innovation and Entrepreneurship Competition in Shanghai"
About novamab
The company was founded in Zhoupu International Medical Park，Shanghai
About Novamab
About NovamabThe company concept can be started from the company name. The word nova in Novamab comes from Latin, meaning new, meaning "new". Mab is the abbreviation of monoclonal antibody, so Novamab means new antibody, while the development of VHH antibody has only been more than 20 years, and it is also a new antibody in the field of antibody research and development, so the two correspond to each other.
The "Y" shape in the company's icon represents the structural shape of the VHH antibody that lacks the light chain, and echoes with the VHH antibody again; In addition, the circular part of the icon is similar to a shield, indicating our desire and determination to defend human health, while the stars symbolize our good expectations for VHH antibody and ourselves. We hope that camel (camel and Luo) antibody can become a new star in the field of antibody medicine and start human future health.
About NovamabDr. Yakun Wan, founder and CEO of Novamab, has 19 years of VHH antibody research experience and is a leading figure in the field. He previously worked at the Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences, and Southeast University. Dr. Wan also conducted postdoctoral research at the University of Texas at Austin, Baylor College of Medicine, and the American Institute of Systems Biology.
Dr. Wan has been honored with several awards, such as the "Hundred Talents Plan" by Shanghai Institute of Medicine, the Six Talent Peak Plans by Jiangsu Province, the "High-level Creative Talents Plan" by the Ministry of Education, and the "New Century Excellent Talents" award. He was also acknowledged as an "Outstanding Innovation and Entrepreneurship Talent" in 2021 and a "Pudong New Area Pearl Talent Leader" in 2024. Under his guidance, Novamab was recognized as one of China's top 50 innovative pharmaceutical enterprises in 2020 and a top 100 innovative seed enterprise in 2022, specialized and sophisticated enterprises that produce new and unique products in 2022.
Dr. Wan has authored over 70 scientific papers, with over 50 as first or corresponding author in SCI-indexed journals. He holds over 120 invention patents, 45 of which are authorized, and has led projects funded by Shanghai Biopharmaceutical Innovation and Development Project the Shanghai Science and Technology Innovation Fund and the National Natural Science Foundation, among others.
Dr. Wan founded China's first VHH antibody R&D team in drug development, partnering with top pharmaceutical firms to progress several products to clinical phases. Novamab, with a complete R&D, pilot testing, and GMP production system, is uniquely positioned to handle full-process VHH antibody development in China. The 500L Pichia pastoris GMP pilot production workshop fills a significant industry void. Dr. Wan's team created the world's first inhaled VHH antibody drugs, LQ036 and LQ043H, targeting lL-4Rα and TSLP, respectively. These drugs are intended for patients with moderate-to-severe asthma, providing rapid local effects and low toxicity.
About Novamab
